Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands |
Mar. 31, 2019 |
Oct. 31, 2018 |
Aug. 01, 2018 |
Jul. 02, 2018 |
Jun. 30, 2018 |
---|---|---|---|---|---|
Business Combination, Liabilities Arising from Contingencies, Amount Recognized | $ 6,700 | ||||
Exosome Diagnostics, Inc [Member] | |||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 325,000 | $ 325,000 | |||
Business Combination, Liabilities Arising from Contingencies, Amount Recognized | 1,800 | ||||
QT Holdings Corporation [Member] | |||||
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 51,000 | $ 51,000 | |||
Business Combination, Liabilities Arising from Contingencies, Amount Recognized | 4,900 | ||||
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member] | |||||
Derivative, Notional Amount | $ 380,000 | ||||
CCXI [Member] | |||||
Investments, Total | $ 18,800 | $ 18,800 |
X | ||||||||||
- Definition Aggregate notional amount specified by the derivative(s). Expressed as an absolute value. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|